India's Suven Pharma gains; Goldman Sachs starts with 'buy'

Cohance Lifesciences

08/04/2025 07:27

** Suven Pharmaceuticals SUVH.NS rises 2.1% to 1,074 rupees after dropping 6.4% in the last two sessions amid a broader market drop triggered by Trump tariffs

** Day's rise comes after Goldman Sachs starts coverage with "buy", sets PT at 1,350 rupees - potential upside of 28.2% in the next 12 months

** Brokerage expects structural growth rebound for co starting this fiscal year, driven by sustained traction for its top five drugs, new drug approvals

** YTD, stock falls 7.5%

 (Reporting by Bharath Rajeswaran in Bengaluru)

 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))